Search

Aurinia Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

16.36 -1.15

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

16.48

Max

16.69

Schlüsselkennzahlen

By Trading Economics

Einkommen

3.1M

37M

Verkäufe

5.5M

83M

KGV

Branchendurchschnitt

6.895

47.946

EPS

0.28

Gewinnspanne

44.958

Angestellte

128

EBITDA

4.8M

55M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+8.76% upside

Dividenden

By Acuity

Nächstes Ergebnis

3. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

218M

2.1B

Vorheriger Eröffnungskurs

17.51

Vorheriger Schlusskurs

16.36

Aurinia Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

9. Okt. 2026, 20:06 UTC

Aurinia Pharmaceuticals Inc shares are advancing, continuing their upward trajectory since Thursday's close, amid generally positive market conditions in the biotechnology sector.

8. Okt. 2026, 20:01 UTC

Aurinia Pharmaceuticals Inc shares are advancing, recovering from a mid-morning dip to near the day's high, following a higher trend since Wednesday's close.

7. Okt. 2026, 19:45 UTC

Aurinia Pharmaceuticals Inc is trading higher, reaching a peak earlier today, but remains below its 20-day moving average after six consecutive lower closes.

6. Okt. 2026, 23:10 UTC

Aurinia Pharmaceuticals Inc. declines in after-market trading, closing at its lowest point of the day and remaining below its 20-day moving average.

2. Okt. 2026, 20:07 UTC

Aurinia Pharmaceuticals Inc shares fell, marking a fifth consecutive session of lower closes, and remain significantly below their 20-day moving average.

1. Okt. 2026, 22:50 UTC

Declining in after-market, Aurinia marks fourth straight session lower.

29. Sept. 2026, 20:07 UTC

Aurinia Pharmaceuticals Inc shares fell, reversing from an earlier rise, and are currently positioned around the midpoint of their one-month trading range.

24. Sept. 2026, 20:03 UTC

Aurinia Pharmaceuticals Inc is trading higher amid gains in the Biotechnology sector, remaining above its 20-day moving average and within its one-month range.

23. Sept. 2026, 20:07 UTC

Aurinia Pharmaceuticals Inc shares fell sharply, continuing a decline from Tuesday's close amid a broader market trend of lower performance.

22. Sept. 2026, 22:01 UTC

Aurinia Pharmaceuticals Inc is declining in after-market trading, influenced by broader market pressures and an unexpected contraction in the U.S. Richmond Fed Manufacturing Index.

16. Sept. 2026, 19:22 UTC

News

Aurinia Pharmaceuticals Inc shares are significantly higher after reporting a substantial increase in quarterly revenue and a rise in net income from LUPKYNIS sales.

15. Sept. 2026, 19:56 UTC

Aurinia Pharmaceuticals Inc. shares are trading lower amid broader market sentiment influenced by anticipated Federal Reserve rate hikes and rising Treasury yields.

14. Sept. 2026, 20:07 UTC

Aurinia Pharmaceuticals shares are higher amid market volatility and inflation concerns ahead of the Federal Reserve's interest rate decision.

10. Sept. 2026, 20:06 UTC

Aurinia Pharmaceuticals shares are lower today, influenced by broader market declines amid macroeconomic factors, including the European Central Bank's interest rate hike.

9. Sept. 2026, 20:41 UTC

Aurinia Pharmaceuticals Inc shares are higher in after-market trading, showing increased investor interest despite no specific company news, remaining above their 20-day moving average.

8. Sept. 2026, 23:36 UTC

Aurinia Pharmaceuticals Inc is trading lower in after-market hours, with no specific news identified to explain the movement. The stock remains within its one-month trading range.

1. Sept. 2026, 20:08 UTC

Aurinia Pharmaceuticals is declining amid broader market losses and rising inflation concerns, with no specific company news identified to explain the movement.

26. Aug. 2026, 20:08 UTC

News

Aurinia Pharmaceuticals shares are lower amid broader Biotechnology sector weakness. A Form 4 filing revealed a $355,000 insider share sale by Chief Legal Officer Stephen P. Robertson.

25. Aug. 2026, 19:36 UTC

Aurinia Pharmaceuticals Inc is trading higher amid a positive market environment, despite pulling back from earlier session highs. No specific news was identified.

24. Aug. 2026, 22:01 UTC

Aurinia Pharmaceuticals Inc shares are lower in after-market hours, continuing a trend of declines observed over the past three sessions. No specific news was identified.

21. Aug. 2026, 23:06 UTC

Aurinia Pharmaceuticals Inc. shares are higher in after-market hours, reflecting routine trading activity and maintaining a position above the 20-day moving average.

20. Aug. 2026, 21:46 UTC

Aurinia Pharmaceuticals Inc shares are trading lower in after-market hours. No specific news was identified to explain the decline.

19. Aug. 2026, 23:02 UTC

News

Aurinia Pharmaceuticals settled patent litigation with Teva, securing exclusivity for voclosporin until December 2036. Shares rose in after-hours trading following the announcement.

18. Aug. 2026, 19:56 UTC

Aurinia Pharmaceuticals Inc is trading higher today, though no specific news has been identified. Rising Treasury yields may pose challenges for equities.

17. Aug. 2026, 20:02 UTC

Social Media

Aurinia Pharmaceuticals shares are lower amid broader market declines and rising crude oil prices, despite some social media chatter about potential buyout interest.

14. Aug. 2026, 19:26 UTC

Aurinia Pharmaceuticals shares are higher today, rebounding after earlier volatility amid broader market concerns over disappointing U.S. retail sales figures.

13. Aug. 2026, 19:56 UTC

News

Aurinia Pharmaceuticals shares are lower today, despite ongoing sales growth of Lupkynis and a recent acquisition of Kezar Life Sciences.

11. Aug. 2026, 20:06 UTC

Aurinia Pharmaceuticals Inc shares are trading lower today, continuing a trend of three consecutive daily declines amid no specific news to explain the movement.

10. Aug. 2026, 20:06 UTC

News

Aurinia Pharmaceuticals shares decline following multiple downgrades from research firms, despite Royal Bank of Canada raising its price target to $16.00.

7. Aug. 2026, 19:16 UTC

News

Aurinia Pharmaceuticals shares are lower today, despite earlier gains. RBC Capital raised the price target to $16.00 from $15.00, maintaining a Sector Perform rating.

Peer-Vergleich

Kursveränderung

Aurinia Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

8.76% Vorteil

12-Monats-Prognose

Durchschnitt 18 USD  8.76%

Hoch 21 USD

Tief 16 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Aurinia Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

3 ratings

2

Buy

1

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
help-icon Live chat